Pharmacokinetics and tissue distribution of psammaplin A, a novel anticancer agent, in Mice

Archives of Pharmacal Research

Volumn 35, Issue 10, 2012, Pages 1849-1854

  Kim, Hak Jae ^a   Kim, Tae Hwan ^b   Seo, Won Sik ^c   Yoo, Sun Dong ^b   Kim, Il Han ^a   Joo, Sang Hoon ^c   Shin, Soyoung ^d   Park, Eun Seok ^b   Ma, Eun Sook ^c   Shin, Beom Soo ^c  

^a Seoul National University Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Wonkwang University   (South Korea)

Author keywords

Pharmacokinetics; Psammaplin A; Stability; Tissue distribution

Indexed keywords

ANTINEOPLASTIC AGENT; PSAMMAPLIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TISSUE LEVEL; IN VITRO STUDY; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PARTITION COEFFICIENT; TANDEM MASS SPECTROMETRY; TISSUE HOMOGENATE;

ANIMALS; ANTINEOPLASTIC AGENTS; DISULFIDES; DNA MODIFICATION METHYLASES; DRUG STABILITY; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED ICR; TISSUE DISTRIBUTION; TYROSINE;

EID: 84872102191     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-1019-5     Document Type: Article

References (22)

1. Ahn, M. Y., Jung, J. H., Na, Y. J., and Kim, H. S., A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol., 108, 27-33 (2008).
2. Arabshahi, L. and Schmitz, F. J., Brominated tyrosine metabolites from an unidentified sponge. J. Org. Chem., 52, 3584-3586 (1987).
3. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., and Beliles, R. P., Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health, 13, 407-484 (1997).
4. Davie, J. R., Covalent modifications of histones: expression from chromatin templates. Curr. Opin. Genet. Dev., 8, 173- 178 (1998).
5. Egger, G., Liang, G., Aparicio, A., and Jones, P. A., Epigenetics in human disease and prospects for epigenetic therapy. Nature, 429, 457-463 (2004).
6. Esteller, M., Relevance of DNA methylation in the management of cancer. Lancet Oncol., 4, 351-358 (2003).
7. Fouladi, M., Histone deacetylase inhibitors in cancer therapy. Cancer Invest., 24, 521-527 (2006).
8. Glozak, M. A. and Seto, E., Histone deacetylases and cancer. Oncogene, 26, 5420-5432 (2007).
9. Grignani, F., De, Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., Seiser, C., Grignani, F., Lazar, M. A., Minucci, S., and Pelicci, P. G., Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature, 391, 815-818 (1998).
10. Jones, P. A. and Baylin, S. B., The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3, 415-428 (2002).
11. Kim, D., Lee, I. S., Jung, J. H., Lee, C. O., and Choi, S. U., Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer Res., 19, 4085-4090 (1999a).
12. Kim, D., Lee, I. S., Jung, J. H., and Yang, S. I., Psammaplin A, a natural bromotyrosine derivative from a sponge, possesses the antibacterial activity against methicillinresistant Staphylococcus aureus and the DNA gyraseinhibitory activity. Arch. Pharm. Res., 22, 25-29 (1999b).
13. Kim, D. H., Shin, J., and Kwon, H. J., Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp. Mol. Med., 28, 47-55 (2007).
14. Kim, H. J., Kim, J. H., Chie, E. K., Young, P. D., Kim, I. A., and Kim, I. H., DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat. Oncol., 7, 39-48 (2012).
15. Litterst, C. L., Mimnaugh, E. G., Reagan, R. L., and Gram, T. E., Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab. Dispos., 3, 259-265 (1975).
16. Nan, X., Ng, H. H,, Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., and Bird, A., Transcriptional repression by methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 393, 386-389 (1998).
17. Nicholas, G. M., Eckman, L. L., Ray, S., Hughes, R. O., Pfefferkorn, J. A., Barluenga, S., Nicolaou, K. C., and Bewley, C. A., Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-S-conjugate amidase. Bioorg. Med. Chem. Lett., 12, 2487-2490 (2002).
18. Park, Y., Liu, Y., Hong, J., Lee, C.-O., Cho, H., Kim, D.-K., Im, K. S., and Jung, J. H., New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis. J. Nat. Prod., 66, 1495-1498 (2003).
19. Piña, I. C., Gautschi, J. T., Wang, G. Y., Sanders, M. L., Schmitz, F. J., France, D., Cornell-Kennon, S., Sambucetti, L. C., Remiszewski, S. W., Perez, L. B., Bair, K. W., and Crews, P., Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem., 68, 3866-3873 (2003).
20. Shin, J., Lee, H. S., Seo, Y., Rho, J. R., Cho, K. W., and Paul, V. J., New bromotyrosine metabolites from the sponge Aplysinella rhax. Tetrahedron, 56, 9071-9077 (2000).
21. Tabudravu, J. N., Eijsink, V. G., Gooday, G. W., Jaspars, M., Komander, D., Legg, M., Synstad, B., and van, Aalten, D. M., Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge Aplysinella rhax. Bioorg. Med. Chem., 10, 1123-1128 (2002).
22. Watt, F. and Molloy, P. L., Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev., 2, 1136-1143 (1988).